Specifically, the results indicate that a proportion of patients receiving eight weeks of treatment with VGV-1 and no additional anti-HIV therapy experienced a decrease in viral load at day 150 that diminished at day 240.
Additionally, in aggregate, VGV-1 treated patients demonstrated positive changes in immune markers associated with HIV infection and proviral peripheral blood mononuclear cells (PBMCs). Proviral PBMCs are cells that have been infected with HIV and produce additional copies of the virus.
“This is the first placebo-controlled study of VGV-1 and confirms the biological activity of the product. We are encouraged by the results as they appear to be consistent with those of our four previous clinical trials,” said Harry Zhabilov, executive vice president of R&D for the company.